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ABSTRACT 
Objective: To conduct a systematic review of cost-effectiveness analyses of trastuzumab in patients with metastatic breast cancer overexpressing 
human epidermal growth factor receptor 2.  
Methods: A systematic review for the years 1998 to 2013 was conducted. A survey of the scientific literature was performed using six electronic 
databases, two search tools on the internet and a manual search of references using search strategies for each database. The selected studies were 
assessed for quality according to specific methodology. Data analysis was performed by converting the costs and by observations made from the 
incremental cost-effectiveness ratios of trastuzumab.  
Results: From a detailed analysis of 521 retrieved articles, 13 articles were selected for this review. The treatment regimens adopted for cost-
effectiveness were varied. Eight studies compared treatment with trastuzumab as first line for metastatic disease, and five studies compared 
treatment with trastuzumab as the second line. All the studies were using trastuzumab as second-line treatment was not considered a cost-effective 
intervention. The analyses used different thresholds to determine whether treatment with trastuzumab was cost-effective as well as to determine 
differences in modeling costs, outcomes and treatment patterns.  
Conclusion: The use of trastuzumab, alone or combined, was cost-effective as first-line treatment. Differences were found in the quality of the 
included studies. Conducting new cost-effectiveness analyses of trastuzumab in metastatic breast cancer is required, in alliance with political, social 
and administrative factors, to help decision makers concerning its incorporation. 
Keywords: Trastuzumab, Cost effectiveness, Breast cancer, Systematic review. 
 
INTRODUCTION 
According to estimates of the National Cancer Institute (Instituto 
Nacional do Câncer José Alencar Gomes da Silva-INCA), in 2014 and 
2015, there will be approximately 576,000 new cases of cancer, of 
which 57,000 will be cases of female breast cancer. Breast cancer is 
the most frequent neoplasm in women from the Southeast, South, 
Midwest and Northeast regions of Brazil and the second most 
prevalent neoplasm in the North region, where cervical cancer is the 
leading neoplasm [1]. 
Approximately 30-50% of patients diagnosed in the initial stages 
will develop a metastatic disease. In this incurable phase of the 
disease, the therapies aim to prolong the survival and provide 
palliative control of symptoms [2]. The over expression of human 
epidermal growth factor receptor 2 (HER2) occurs in approximately 
25% of all cases of breast cancer and is associated with lower 
disease-free interval and survival [3]. Trastuzumab, a monoclonal 
antibody directed at HER2, has been increasing the response, 
progression-free survival and/or overall survival rates in metastatic 
breast cancer [2, 4, 5]. 
Many countries have economic pressures from their healthcare 
systems and society to provide coverage for monoclonal antibodies 
due to their high prices [3]. Treatment with trastuzumab is unlikely 
to be affordable by most patients, unless it is covered by the public 
or private healthcare system [6]. The Ministry of Health has 
incorporated trastuzumab in the Coverage table of the Sistema Único 
de Saúde (SUS), the Brazilian Unified Health System, for initial and 
advanced breast cancer, excluding the metastatic phase [7, 8]. The 
main issues regarding the cost-effectiveness of trastuzumab use in 
metastatic breast cancer have remained unanswered in the 
literature, because data used to support these demands are 
dispersed across different studies from different organizational 
contexts. The studies found are often small-scale and 
methodologically flawed and refer to non-controlled clinical trials, 
making them unsuitable for formal meta-analyses [6]. 
It is important to consider that the successful development of a 
systematic review generates a reliable estimate of the effect of the 
intervention studied [9]. Therefore, a systematic literature review 
was performed to identify relevant articles concerning the cost-
effectiveness of trastuzumab for metastatic breast cancer in patients 
with over expression of HER2 compared with other chemotherapy 
regimens adopted. The present systematic review secondarily aimed 
to add supporting information to future discussions on the cost-
effectiveness ratio of trastuzumab and subsequent incorporation of 
trastuzumab by SUS for the treatment of metastatic breast cancer. 
MATERIALS AND METHODS 
Study design 
A systematic review of the literature was performed with the 
following guiding question: “Is trastuzumab more cost-effective than 
other anticancer agents in patients with metastatic breast cancer 
with over expression of HER2?” 
Data sources 
The following electronic databases were used to identify published 
studies on the cost-effectiveness of trastuzumab for metastatic 
breast cancer: MEDLINE (via PubMed), EMBASE (via Portal Saúde 
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Baseadaem Evidências), LILACS (via BIREME), Web of Science and 
Science Direct. Registers from the Cochrane Collaboration (via 
BIREME), the National Health System of the United Kingdom 
through the NHSEED database and other international technological 
evaluation agencies of the International Network of Agencies for 
Health Technology Assessment (INAHTA) were also analyzed. To 
retrieve additional studies, the search was expanded using the 
Google scholar search engine. As a complement, a manual search for 
references cited in the relevant publications obtained was 
performed in the mentioned databases. The search was limited to 
the period from 1998 to 2013, and there were no language 
restrictions in this step.  
The search strategy was designed based on the following descriptors 
and their synonyms of each database: MeSH for MEDLINE 
(trastuzumab AND breast neoplasms AND cost-benefit analysis AND 
secondary), EmTree for EMBASE (trastuzumab AND “cost 
effectiveness analysis” AND “breast metastasis”)and Decs for LILACS 
[(trastuzumabe OR trastuzumab OR herceptin) AND ("custo-
efetividade" OR "cost-benefit analysis" OR "cost effectiveness" OR 
"análisis costo-beneficio" OR "análise custo-benefício") AND 
("neoplasias da mama" OR "câncer de mama" OR "breast neoplasms" 
OR "neoplasias de la mama") AND (secundário OR metastático OR 
secondary OR metastatic OR secundario)]. For the remaining 
electronic databases, keywords relating to the disease (“metastatic 
breast cancer”), intervention (“trastuzumab”) and type of economic 
analysis (“cost effectiveness”) were used with the necessary 
adaptations for each bibliographic database.  
Studies from each database were placed in Microsoft® Excel (version 
2010) spreadsheets to eliminate duplicates and create a reference 
database. 
Selection of studies 
Studies from the bibliographic search were independently analyzed 
by two researchers (T. S. A. and T. F. G. S.) to manually eliminate 
duplicate studies. The authors, titles and journal names were 
compared, along with the volume, number and year of the 
publication. The remaining studies were examined based on their 
title and abstract. Original studies that mentioned the technology, 
health problem studied and the type of economic evaluation 
(trastuzumab, metastatic breast cancer and cost-effectiveness 
analysis) in Portuguese, Spanish and English were selected. 
Comments, editorials, letters, case studies, review articles, 
conference posters, systematic reviews and meta-analyses were 
excluded, as were duplicate studies performed by the same research 
group addressing the same object of the initial study. Studies that 
did not include information on costs and outcomes of the 
intervention, that addressed the impact of the metastatic breast 
cancer management costs on the health budget or that addressed the 
costs of therapeutic interventions used to correct adverse reactions 
caused by trastuzumab were also excluded from the review.  
Articles selected as potentially relevant continued to the next step, in 
which they were thoroughly evaluated based on a full reading of the 
text, and only those that met al. l eligibility criteria, mentioned 
below, were included in the systematic review. 
• Study objective: To evaluate the cost-effectiveness ratio of 
trastuzumab or use it as a comparator. 
• Population: Patients with metastatic breast cancer over 
expressing HER2, regardless of age. 
• Intervention: Trastuzumab, both as monotherapy, to treat 
patients who received one or more chemotherapy treatments for 
metastatic breast cancer, or in combination with taxanes (paclitaxel 
or docetaxel), to treat patients who did not receive chemotherapy 
for their metastatic diseases. 
• Control or comparison: Other anticancer drugs or no drugs. 
• Outcomes: Overall survival, quality-adjusted life years (QALY), 
life years gained, mortality, time to progression and progression-free 
survival. 
Disagreements in both steps regarding the inclusion or exclusion of 
studies in the review were resolved by a third reviewer (G. B. G. M.).  
Data extraction and quality assessment of studies 
The selected articles were fully read by the two reviewers, and the 
items listed below were independently extracted to a spreadsheet:  
• Characteristics of the studies: identification of the article (title, 
author, journal, volume, number, year and country of publication), 
intervention and comparators used;  
• Clinical characteristics of the treatments: line of therapy of the 
metastatic disease, previous use of trastuzumab, performance of a 
diagnostic test for the HER receptor, dosage;  
• Characteristics of cost-effectiveness analyses: efficacy data sources, 
economic model, time horizon, perspective adopted, discount rate, 
drug costs, other costs, currency, outcomes evaluated, incremental 
cost-effectiveness ratio (ICER) and the author’s conclusion. 
Differences in the extraction of information were resolved by 
consensus with a third reviewer upon the reassessment of the 
original article.  
The quality assessment was independently performed by two 
reviewers adopting the format used by Teerawattananon et al. [10] 
with two different approaches. First, the practices reported for 
economic evaluation studies were assessed, namely, (a) the 
expression of the perspective used; (b) the description of the 
interventions to be compared; (c) the relationship between time 
horizon and discount; (d) the ICER data; (e) sensitivity analysis; and 
(f) the financial support statement.  
The studies were assessed in a second stage according to the quality of 
the evidence used [11, 12]. The items comprising this assessment were: 
(a) the size of the clinical effects; (b) adverse events and complications; 
(c) basal clinical data; (d) the use of resources; (e) costs; and (f) utility 
(only applicable to cost-utility analyses). Coyle & Lee [11] asserted that it 
is necessary to identify specific factors related to the data sources for the 
main parameters that determine their suitability regarding the economic 
analysis in question. The data sources of each component were ranked 
from 1 to 6 in descending order. Studies are class 1 if the parameters are 
derived from the most reliable data sources. This quality assessment was 
summed using a table, in which the results found in each study were 
organized.  
Synthesis and analysis of results  
Data were extracted and interpreted regarding the ICER of 
trastuzumab (combined or alone) in metastatic breast cancer. The 
costs were converted to Brazilian Real using the conversion tool 
available on the website of the Central Bank of Brazil (Banco Central 
do Brasil) [13], and the results were compared with the budget 
ceiling recommended by the World Health Organization (WHO), but 
in Brazilian currency. According to the WHO, developing countries 
should adopt the threshold of up to three times the value of their 
gross domestic product (GDP) per capita in cost-effectiveness 
analyses of new technologies [14, 15]. Information on the GDP and 
Brazilian population was obtained from the website of the Brazilian 
Institute of Geography and Statistics (Instituto Brasileiro de 
Geografia e Estatística) [16]. 
The selected studies presented the use of trastuzumab in two 
different ways: as a first-or second-line therapy for metastatic breast 
cancer. The use of trastuzumab was performed alone or combined 
with other drugs. Given these characteristics, the conclusions of the 
cost-effectiveness analyses regarding the introduction of 
trastuzumab were grouped according to the existence of previous 
treatment of the metastatic diseases of patients. 
RESULTS 
Search and selection of studies 
In total, 521 studies were identified. Of these, 161 were excluded 
due to being duplicates, leaving 360 studies. A total of 294 studies 
were discarded after reading their titles because they did not meet 
the criteria specified for this step (studies related to the cost-
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effectiveness analysis of trastuzumab in metastatic breast cancer). 
Studies on the use of trastuzumab as an adjuvant and neoadjuvant 
therapy for breast cancer were excluded. Studies whose titles were 
not clear regarding the inclusion criteria were added to the 
subsequent step of reading of the abstracts, along with the other 
studies identified. A total of 66 studies were selected for reading of 
their abstracts. Forty-two studies were excluded by the same criteria 
mentioned previously, resulting in 24 studies to be fully read. No 
studies were excluded for being in a different language from those 
established for the present review. No additional studies were 
included by searching gray literature or by manually searching the 
references cited in the relevant publications obtained. 
In the second step of the selection, 11 studies were excluded because 
10 were conference posters, and 01 was an abstract of a technology 
evaluation report, whose objective was not to evaluate trastuzumab 
but to evaluate another drug. Finally, 13 studies comprised the 
present systematic review.  
Data extraction and quality assessment of studies 
Regarding the publication countries, 12 studies involved countries 
from North America and Europe. Only one study was developed in 
Brazil. 
The studies were conducted within the last 10 years. The 
therapeutic regimens adopted in the cost-effectiveness analyses 
differed: eight studies compared the treatment with trastuzumab as 
a first-line therapy for metastatic disease, and five studies compared 
it as a second-line therapy; three of these latter studies used 
trastuzumab as a comparator in the evaluation of the cost-
effectiveness ratio of other therapies, not as an intervention.  
Table 1 shows the main characteristics of the studies. Table 2 shows 
the characteristics related to the cost-effectiveness analyses. All the 
studies were grouped according to the use of trastuzumab as a first-
and second-line treatment. 
  
Table 1: Main characteristics of the studies included 
Authors Year Country Intervention Comparator HER2 test 
Trastuzumab as 1st line therapy for metastatic disease 
[17] 2012 Greece trast+dxt docetaxel not reported 
[18] 2004 USA IHC test, trast+txt for+3 paclitaxel IHC 
IHC test confirmed by FISH for IHC+2 and+3, 
trast+txt  
IHC confirmed 
by FISH for 
IHC+2 and+3 
IHC test confirmed by FISH for IHC+2, trast+txt IHC confirmed 
by FISH for 
IHC+2 
IHC test, trast+txt for+2 and+3 IHC 
FISH test, trast+txt for positive results FISH 
trast+txt none 
[19] 2011 United 
Kingdom 
trast+anastrozole anastrozole not reported 
[20]  2009 USA trast+chemotherapy chemotherapy IHC and/or 
FISH (without 
details) 
[21] 2008 Sweden IHC test, trast+dxt for+3 docetaxel IHC 
IHC test, trast+dxt for+2 and+3 IHC 
IHC test confirmed by FISH for IHC+2 and+3, 
trast+dxt for FISH-positive results 
IHC confirmed 
by FISH for 
IHC+2 and+3 
FISH test, trast+dxt for FISH-positive results FISH 
[22] 2005 Norway trastuzumab+docetaxel docetaxel IHC 
trastuzumab+anthracycline+cyclophosphamide anthracycline+cyclophosphamide 
trastuzumab+paclitaxel paclitaxel 





[24] 2008 France trastuzumab+paclitaxel  conventional chemotherapy IHC+3 
Trastuzumab as 2nd line therapy for metastatic disease 
[25] 2005 Italy Cyclophosphamide+low-dose methotrexate  Trastuzumab+paclitaxel not reported 
[26] 2012 United 
Kingdom 
Lapatinib+capecitabine Trastuzumab+capecitabine not reported 
[27] 2012 Brazil Lapatinib+capecitabine Trastuzumab+capecitabine not reported 
[28] 2010 Sweden Trastuzumab+capecitabine Capecitabine IHC or FISH 
[29] 2005 Belgium Trastuzumab no trastuzumab (details not reported) FISH 
Legend: dxt: docetaxel; USA: United States of America; FISH: fluorescence in situ hybridization; IHC: immunohistochemical; trast: trastuzumab; txt: paclitaxel. 
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Legend: cap: capecitabine; tab: tablet; CTX: cyclophosphamide; lap: lapatinib; MTX: methotrexate; QALY: quality-adjusted life years; CT: 
chemotherapy; trast: Trastuzumab. 
 
Regarding effectiveness, most economic evaluations based their 
efficacy estimates on the results from four controlled randomized 
clinical trials: three economic evaluations based on Marty et al. [30], 
three based on Slamon et al. [31], three based on Von Minckwitz et 
al. [32] and one evaluation based on Kaufman et al. [33]. Four 
economic evaluations used results from non-randomized studies, 
including one comparison of the mean survival between two single-
arm clinical studies [25], one phase II clinical trial [29], one before-
and-after design study of a single treatment center [23] and one 
comparison of the results between four treatment centers that 
treated patients with trastuzumabe, with six centers that did not 
treat patients with trastuzumab [24]. Similar to the effectiveness, 
comparators and treatment regimens were also selected based on 
randomized controlled clinical trials. The trastuzumab dose was very 
similar among the studies, ranging from a loading dose of 0.004 g/kg, 
followed by 0.002 g/kg weekly, to 0.008 g/kg as the loading dose and 
0.006 g/kg every 3 weeks. There was a wide variety of other drugs 
used as comparators that were already used in the treatment of the 
metastatic disease (anastrozole, anthracyclines, capecitabine, 
cyclophosphamide, lapatinib, methotrexate, docetaxel, and paclitaxel) 
[34]. Most studies reported using one or two biochemical tests to 
determine the HER2 status in the tumor cell membrane. However, only 
Elkin et al. [18] and Lidgren et al. [21] listed the cost-effectiveness 
results for each HER2 test strategy used. 
The Markov model was the most used economic method among the 
evaluations. Two (progression-free and post-progression) to three 
(stable disease, response, progressive disease) stages were used, 
followed by death. There was great variation between the time 
horizons adopted by the studies, from 24 weeks to the lifetime of the 
patient.  
Most of the evaluations used direct costs, from the perspective of the 
national health system, whereas two evaluations used the society’s 
perspective. The resources used varied drastically between these 
evaluations. For example, one of them used only medical visits and 
the administration of drugs [17], whereas another evaluation also 
used palliative care [19]. In addition, five evaluations did not report 
the use of the discount rate in the costs or outcomes [21, 23-25, 29], 
and there was even one evaluation [28] that reported that their 
costs and outcomes were not discounted (0%). 
Similar to the effectiveness data, all economic evaluations also 
obtained the values of outcomes from studies published in the 
literature.  
All the studies calculated the ICER, shown in table 3. Because two 
studies [25, 27] reported the ICER regarding two outcomes different 
from the remaining studies, this ratio was removed from the table, 
leaving only calculations related to life years and QALY gained. 
 











Trastuzumab as 1st line therapy for metastatic disease 
[17] €27323.98 0.729 0.449 37759.97 €61323.33 Cost-effective 
[18] 
IHC confirmed by FISH for 
IHC+2 and+3, trast+txt vs 
no test, txt 
US$10388 Not applicable 0.08 Not applicable  US$125100 Cost-effective 
[18] 
FISH, trast+txt for positives 
vs IHC confirmed by FISH 
for IHC+2 and+3, trast+txt 
US$1036 Not applicable 0.01 Not applicable  US$145400 Cost-effective 
[19] £37899 0.669 0.545 Not reported £69514 Not cost-
effective 
[20]  US$47728 Not applicable 0.56 Not applicable US$85676 Not reported 
[21] 
IHC confirmed by FISH for 
IHC+2 and+3, trast+dxt vs 
no test, dxt 
SEK85064 Not reported  0.176 SEK332252  SEK485039 Cost-effective 
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[21] 
FISH, trast+dxt vs IHC 
confirmed by FISH for 
IHC+2 and+3, trast+dxt 
SEK8442 Not reported  0.015 SEK384427 SEK561207 Cost-effective 
[22] €44196 0.3 to 0.7 Not 
applicable 
€69212 to €162417 Not applicable Not cost-
effective 
[23] €26812 1.5 Not 
applicable 
€17874.66 Not applicable Cost-effective 
[24] €21980 1.43 Not 
applicable 
€15370 Not applicable Cost-effective 
Trastuzumab as 2st line therapy for metastatic disease 






free life years 
Not applicable Not cost-
effective 
[26] €107 0.019 0.031 Dominated Dominated Not cost-
effective 
[27] R$18430 0.23 0.131 Dominated Dominated Not cost-
effective 
[28] €33980 Not applicable 0.35 Not applicable €98329 Not cost-
effective 




Not applicable High cost-
effectiveness 
ratio 
Legend: dxt: docetaxel; FISH: fluorescence in situ hybridization; ICER: incremental cost-effectiveness ratio; IHC: immunohistochemical; QALY: 
quality-adjusted life years; trast: trastuzumabe; txt: paclitaxel. 
 
Of the eight evaluations that used trastuzumab as a first-line therapy, 
five concluded that this drug could be considered cost-effective. Of 
these, three evaluations [17, 21, 23] specified the threshold against 
which the ICER was compared. One evaluation related a minimum 
value that the society was willing to pay (“willingness to pay”) for 
health improvements [18], and another reported that the ICER was 
“considered as acceptable in a developed country where the health 
system is willing to offer the population full access to innovative 
treatments.” [24]. All the studies that used trastuzumab as a second-
line therapy did not consider the intervention as cost-effective. 
Regarding the first approach of the quality assessment (table 4), and 
following the methodology for economic evaluations [10], the least 
met criteria were the use of the discount rate (53.8%) and disclosure 
of funding sources (61.5%).  
The ICER was calculated in all the studies. Two studies [24, 29] did 
not perform the sensitivity analysis, whereas four did not report the 
perspective used in the evaluations [19-24]. Four other studies [18, 
20, 22, 29] did not adequately describe the comparators used 
(dosage and duration of treatment). 
 
Table 4: Results of the first stage of the quality assessment 
Recommendations Number of studies fulfilling recommendation Percentage (%) 
Perspective specified 09 69.2 
Descriptionof comparators 09 69.2 
Used discounting for costs and/oroutcomes iftime horizonwas>1 year 07 53.8 
Calculated and reported ICER 13 100 
Performed uncertainty analysis 11 84.6 
Disclosed funding sources 08 61.54 
 
Table 5 shows the second approach adapted by Cooper et al. [12]. The 
utilities and base clinical data criteria were not mandatory for every 
article, and thus were the least met criteria. Eight studies used 
randomized controlled clinical trials, measuring end results, to insert 
clinical effects data into economic evaluations, except for five studies 
[20, 23-25, 29]. Only three studies collected their own administrative 
(hospital) data to define the types and amount of resources used 
during the treatment of metastatic breast cancer [23, 24, 29]. 
 
Table 5: Representation of results of the second stage of the quality assessment 
Evidence rank Size of clinical effects/adverse 
events and complications 
[n (%)] 
Base clinical data 
(if applicable) [n 
(%)] 





applicable) [n (%)] 
1+      
1 8 (61.5) 3 (60) 3 (25) 12 (92.3)  
2+      
2   7 (58.3) 1 (7.7)  
3+      
3     8 (100) 
4 4 (30.8) 2 (40)    
5      
6   2 (16.7)   
9 1 (7.7)     
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Summary and analysis of results 
The ICERs were converted to Brazilian Real (R$) to be compared 
with the threshold usually recommended by technology evaluation 
agencies and adopted by the Department of Science and Technology 
of the Ministry of Health (table 6). According to WHO, a technology is 
considered to be very cost-effective if the ICER is less than the GDP 
per capita, cost-effective if the ICER is between 1 and 3 times the 
GDP per capita, and not cost-effective if the ICER is greater than 3 
times the GDP per capita [15]. 
  







ICER (cost per life years) 
(R$) 
ICER (cost per 
QALY) (R$) 
Trastuzumab as 1st line therapy for metastatic disease  
[17] 87521.44 0.729 0.449 120056.84 194925.25 
[18] 
IHC confirmed by FISH for IHC+2 
and+3, trast+txt vs no test, txt 
24170.80 Not applicable 0.08 Not applicable 302135.00 
[18] 
FISH, trast+txt for positives vs IHC 
confirmed by FISH for IHC+2 
and+3, trast+txt 
2410.56 Not applicable 0.01 Not applicable 241056.00 
[19] 144524.05 0.669 0.545 216029.97 265181.74 
[20]  111053.51 Not applicable 0.56 Not applicable 198309.83 
[21] 
IHC confirmed by FISH for IHC+2 
and+3, trast+dxt vs no test, dxt 
30342.33 Not reported 0.176 118514.28 172399.60 
[21] 
FISH, trast+dxt vs IHC confirmed 
by FISH for IHC+2 and+3, trast+dxt 
3011.26 Not reported 0.015 137125.11 200750.66 
[22] 141564.21 0.3 to 0.7 Not 
applicable 
202234.58 to 471880.70 Not applicable 
[23] 85881.52 1.5 Not 
applicable 
57254.35 Not applicable 
[24] 70404.14 1.43 Not 
applicable 
49233.66 Not applicable 
Trastuzumab as 2st line therapy for metastatic disease  
[25] 205523.71 0.477 progression-






[26] 342.73 0.019 0.031 Dominated Dominated 
[27] 18430 0.23 0.131 Dominated Dominated 
[28] 108841.34 Not applicable 0.35 Not applicable 310,975.25 
[29] 10437.05 0.82 life months or 
0.0683 life years 
Not 
applicable 




Based on the R$ 67,206.00 Brazilian threshold (3 × GDP per capita of R$ 22402.00), none of the evaluations reported an ICER that allows 
trastuzumab to be considered cost-effective. 
 
DISCUSSION 
The present review indicated that the use of trastuzumab, alone or 
in combination, was cost-effective as a first-line therapy for 
metastatic disease, in contrast to when it is used as a second-line 
therapy. In the five studies that used trastuzumab as a second-line 
therapy, four authors [26-29] stated that the differences in the drug 
prices were the main responsible factors for the differences between 
the treatments. Bocci et al. [25] stated that their intervention 
(cyclophosphamide+methotrexate) represented a “good value for 
money and efficient use of health care resources”.  
Important limitations were observed in some economic evaluations, 
particularly in those that used non-randomized approaches to 
estimate efficacy data [23,24]. Comparing the results of different 
treatment centers, as performed by Poncet et al. [24], using the time 
(“before-and-after”), as Perez-Ellis et al. [23] did, or making indirect 
comparisons between different clinical trials, as performed by Bocci et 
al. [25], Delea et al. [26] and Machado & Einarson [27], may be biased 
if there are differences between the trials regarding the methods (for 
example, treatment and measurement of results) or characteristics of 
the patients that modify the effects of the compared treatments. There 
is a strong recommendation to use the highest evidence levels when 
assessing the efficacy of interventions. Randomized clinical trials, 
syntheses of systematic reviews and meta-analyses are the most 
robust studies because their design allows controlling for potential 
biases and confounding factors [9, 14, 35]. 
Currently, there are two biochemical assays on the market to determine 
the HER2 status in tumor cell membranes. The immunohistochemical 
(IHC) assay tests the overexpression of the HER2 protein, whereas the 
fluorescence in situ hybridization (FISH) detects the amplification of the 
HER2 gene. This latter test is considered as a gold standard, but it is also 
the most expensive one [36]. 
The studies of Elkin et al. [18] and Lidgren et al. [21] combined the 
use of the HER2 test with the treatment strategy, and this test had an 
important influence on the cost-effectiveness ratio of the therapy. 
When the “test+treatment” strategies were compared, the 
differences between the tests (with the same treatments) could 
already make the strategy cost-effective. These two authors found 
that the most cost-effective strategy is to test all patients using IHC, 
followed by confirmation of IHC2+and IHC3+with FISH, a strategy 
that is consonant with the systematic review conducted by 
Dendukuri et al. [36], and trastuzumab plus chemotherapy for FISH-
positive results. And also testing all patients with FISH and 
treatment of positives, if the threshold values are higher than those 
commonly practiced. 
Another important point raised in the studies analyzed that may 
have generated different conclusions was the value of the drugs and 
resources used in different countries. The prices and expenses may 
vary according to the type of health system and the study’s 
perspective. Any decrease in the costs would result in a subsequent 
decrease in the cost-effectiveness ratio [37]. Matter-Walstra et al. 
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[28], in their sensitivity analysis, showed that, depending on the 
body surface, a decrease of 30-60% in the cost of trastuzumab would 
result in an ICER below the threshold used in the study, indicating 
that the use of trastuzumab would be cost-effective as a second-line 
therapy. 
Some evaluations excluded treatment beyond disease progression, 
whereas others considered trastuzumab waste when calculating its 
cost, a situation that does not always occur in clinical practice. There 
were other differences regarding the use of resources, such as 
considering the monitoring and treatment of adverse reactions, 
palliative care, and pharmaceutical services. All these factors 
contributed to the calculation of the total cost of the treatment, thus 
influencing the cost-effectiveness ratio. For Parkinson et al. [6], the 
rate of adverse reactions and their monitoring and treatment, the 
extension of treatment beyond progression, the level of trastuzumab 
waste and the use of chemotherapy after disease progression most 
likely can only be precisely determined after the widespread use of 
the intervention, instead of using data from a controlled randomized 
clinical trial. 
In the present review, it was also found that the studies analyzed 
used different thresholds and decision analyses when evaluating the 
ICER of trastuzumab. The choice of a cost-effectiveness threshold 
depends on who is making the decision, what is the purpose of the 
analysis, how much the society is willing to pay for health 
improvements, what are the resources available, and how the 
decision maker values health, money and risk [38]. This explains the 
different cost-effectiveness thresholds found in the present review 
because the evaluation of authors from each country (even within 
the same country) was based on each one of the previously 
described factors. The two evaluations [23,24] that reported higher 
estimates for life years gained (approximately 1.5 life years gained) 
provided the lowest ICER, and these estimates may have influenced 
the ICER. This result occurred because these two evaluations used 
results from non-randomized studies, in which selection or 
allocation (patients with a worse prognosis in the comparator arm, 
for example) biases may have occurred that would overestimate the 
efficacy of trastuzumab. 
The findings of the present systematic review are consistent with 
those of other published reviews on the subject. A literature search 
showed five systematic reviews on the cost-effectiveness ratio of 
trastuzumab in metastatic breast cancer: Lewis et al. [39]; Ferrusi et 
al. [40]; Blank et al. [37]; Fleeman et al. [19]; and Parkinson et al. [6]. 
The review by Ferrusi et al. [40] covered breast cancer treatment as 
a whole-initial and metastatic-but the other four reviews evaluated 
only the metastatic phase of the disease. The study by Lewis et al. 
[39] included only two economic evaluations, extracted from the 
submission of Roche to the National Health System (NHS) to obtain 
the trastuzumab registration. The study by Fleeman et al. [19] did 
not include any economic evaluation in their review; therefore, the 
authors decided to make their own cost-effectiveness analysis. The 
systematic review by Blank et al. [37] covered not only trastuzumab 
but also other anticancer drugs and molecular targeted agents. 
However, the authors did not perform a quality assessment. 
Parkinson et al. [6] did not use a formal methodology to assess the 
quality of the studies and only discussed issues that could affect the 
quality of an economic evaluation based on the checklist of 
Drummond et al. [41].  
Regarding the quality assessment of the economic evaluations, the 
methodology used by Lewis et al. [39] and Ferrusi et al. [40] in their 
systematic reviews was the one developed by Drummond et al. [41]. 
This methodology results in a thorough interpretation of economic 
evaluations because it covers all the important items for its 
development and is presented as open questions. To make this 
methodology more practical, Lewis et al. [39] adapted it to a 
checklist with closed questions that could be answered by binary 
categorical variables (yes/no).  
In the present review, the methodology used by Teerawattananon et 
al. [10] was adopted. The advantage of this method is that it 
provides a more thorough analysis of the evidence that was used as 
a basis to develop the economic studies. It was concluded that the 
included studies were of good methodological quality, both in the 
first and in the second approach, because there was little 
heterogeneity among the criteria evaluated. 
The limitation of the present study was that the second approach of 
the quality assessment was not conducted by a third reviewer, a 
strategy that was different from the other steps of the systematic 
review. In addition, conference abstracts were excluded for not 
meeting the eligibility criteria, but they could contain relevant 
information on the cost-effectiveness ratio of trastuzumab for 
metastatic breast cancer. 
CONCLUSION 
The present study aimed to address the cost-effectiveness ratio of 
interventions with trastuzumab in the treatment of metastatic 
breast cancer, investigating whether the existing literature would 
allow drawing any conclusions about this issue. Secondarily, the 
study also allowed exploration of the main drivers of the conflicting 
conclusions among the authors, leading to the thorough examination 
of the cost-effectiveness ratio of trastuzumab for metastatic breast 
cancer. This was possible because the included economic 
evaluations showed differences in the modeling of costs, outcomes, 
treatment patterns between the countries (such as the method for 
HER2 tests) and thresholds considered for a technology to be cost-
effective. 
After converting the values used in the studies to Brazilian Real (R$), 
trastuzumab would not be considered cost-effective in any 
assessment using the Brazilian threshold. However, the differences 
in the use of resources and funding between the various health care 
systems may limit the transferability of foreign results into the 
Brazilian context. To consider trastuzumab as cost-effective for 
metastatic breast cancer, some topics must be considered: first, the 
treatment protocol (combination with other drugs or patients with 
or without recurrence). Second, the decision must also consider the 
use of the HER2 test and which HER2 status (2+and/or 3+, 
confirmed or not by FISH) will receive treatment because this test 
affects the cost-effectiveness results. 
New cost-effectiveness analyses of trastuzumab for metastatic 
breast cancer are required, preferably combined with future 
randomized clinical trials in which data on the cost and effectiveness 
are collected simultaneously with the comparison of groups, 
providing more accurate data and allowing the comparison of the 
adverse effects profile of both therapies. It is also important that 
these economic evaluations cover new drugs already available for 
metastatic breast cancer (e. g., lapatinib and pertuzumab) to 
generate information useful particularly for treatment beyond 
progression (second-line or subsequent treatment). 
Finally, any decisions on the incorporation of trastuzumab for the 
treatment of metastatic breast cancer in Brazil should not be based 
only on economic studies. The decision of introducing a new public 
health intervention should consider multiple factors, including, in 
addition to the effectiveness of the intervention, its safety, the 
financial costs of initiating and maintaining the treatment, the 
monitoring of the clinical results of its use and the necessary 
infrastructure to successfully provide the intervention, as well as the 
political will and equity promotion factors. 
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